A review of pre-operative serum CA125 concentrations in ovarian cancer patients by FIGO stage and by histological type showed that CA125 was elevated in only 50% of stage I ovarian cancer cases and in 69% of mucinous ovarian tumours while being far more prominently expressed in patients with late stage serous tumours [4]. Here, MUC16 is linked to ovarian mucinous neoplasm.